PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
22487171-3	2012	It has been proposed that both the mGluR2 agonist DCG-IV and noradrenaline promote mate recognition memory formation by reducing GABAergic feedback on mitral cells.	dcg	50-53	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	35-41
22202905-6	2012	Moreover, we also found that this significantly enhanced DCG-IV effect in the medial perforant path recorded in slices from pilocarpine-treated rats was due to a significant increase of mGluR2, but not mGluR3 transcripts in the entorhinal cortex using quantitative real-time reverse transcriptase-PCR.	dcg	57-60	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	186-192
21207218-8	2011	The p-Erk1/t-Erk1 ratio significantly increased in the NEG (p < 0.001), whereas the p-Erk2/t-Erk2 ratio significantly decreased in the DCG and DEG (p < 0.001).	dcg	138-141	mitogen activated protein kinase 1	Rattus norvegicus	89-93
21207218-9	2011	The caspase-3 level significantly increased in the DCG compared with that in the DEG (p < 0.001).	dcg	51-54	caspase 3	Rattus norvegicus	4-13
19800940-10	2009	The p-PI3-K and t-CREB protein levels significantly increased in the NEG (P<0.001 and P<0.05, respectively), whereas t-Erk1/2 significantly decreased in the DCG (P<0.01, P<0.01, respectively).	dcg	163-166	mitogen activated protein kinase 3	Rattus norvegicus	125-131
20974202-2	2010	Considering that BDNF protein is anterogradely transported to dopaminergic nerve endings, an autocrine role of BDNF could account for the neuroprotective effect of DCG-IV against the MPP(+)-induced toxicity of dopaminergic terminals.	dcg	164-167	brain derived neurotrophic factor	Homo sapiens	17-21
20974202-2	2010	Considering that BDNF protein is anterogradely transported to dopaminergic nerve endings, an autocrine role of BDNF could account for the neuroprotective effect of DCG-IV against the MPP(+)-induced toxicity of dopaminergic terminals.	dcg	164-167	brain derived neurotrophic factor	Homo sapiens	111-115
20061385-3	2010	Depletion of SgII expression in PC12 cells leads to a decrease in both the number and size of DCGs and impairs DCG trafficking of other regulated hormones.	dcg	94-97	secretogranin II	Rattus norvegicus	13-17
20061385-7	2010	We conclude that SgII is a critical factor for the regulation of DCG biogenesis in neuroendocrine cells, mediating the formation of functional DCGs via its pH-dependent aggregation at the trans-Golgi network.	dcg	65-68	secretogranin II	Rattus norvegicus	17-21
20466822-7	2010	To trace the intracellular action of the inhibitors with intracellular cathepsin L, the activity-based probe biotin-Lys-C5 alkyl linker-Tyr-Leu-epoxide (DCG-04) was used to label the active site of cysteine proteases in 293T lysates.	dcg	153-156	cathepsin L	Homo sapiens	71-82
19800940-12	2009	Caspase-3 protein levels significantly increased in the DCG (P<0.001).	dcg	56-59	caspase 3	Rattus norvegicus	0-9
18448660-7	2008	Evoked responses were suppressed by application of the group II metabotropic glutamate receptor agonist (2S,2"R,3"R)-2-(2",3"-dicarboxycyclopropyl)glycine (DCG-IV), in line with the known sensitivity of mossy fiber-CA3 synapses to this agent.	dcg	156-159	carbonic anhydrase 3	Rattus norvegicus	215-218
19549561-7	2009	The intraventricular injection of DCG-IV (250 pmol) significantly attenuated the [Glu]e increase and significantly increased the survival rate of CA1 neurons.	dcg	34-37	carbonic anhydrase 1	Rattus norvegicus	146-149
19143833-4	2009	The activity-based probe DCG-04, which is an E-64-type inhibitor, was found to label both mature cathepsin B and its zymogen, confirming the zymography data.	dcg	25-28	cathepsin B	Homo sapiens	97-108
19787680-10	2009	Taking ITA haplotype as reference, multivariate regression analysis confirmed the negative (ITG), and positive (DCG, DTG, DCA and DTA) association of specific ACE haplotypes with DN, after adjusting for potential nephropathy-linked covariates.	dcg	112-115	angiotensin I converting enzyme	Homo sapiens	159-162
19841358-8	2009	In our Cox models, patients with a BMI greater than 50 (superobesity; hazard ratio [HR], 1.8; P = .04) or a DCG score greater than or equal to 2 (HR, 3.4; P < .001) had an increased risk of death.	dcg	108-111	cytochrome c oxidase subunit 8A	Homo sapiens	7-10
18299326-6	2008	Truncation analyses reveal the presence of DCG-targeting signals within both the N- and C-terminal regions of SgII, with the putative alpha-helix-containing SgII-(25-41) and SgII-(334-348) acting as sufficient, independent sorting domains.	dcg	43-46	secretogranin II	Homo sapiens	110-114
18299326-7	2008	This study defines sequence features of SgII mediating vesicular targeting in sympathoadrenal cells and suggests a mechanism by which discrete domains of the molecule function in sorting, perhaps by virtue of a particular arrangement in tertiary structure and/or interaction with a specific component of the DCG membrane.	dcg	308-311	secretogranin II	Homo sapiens	40-44
17559977-2	2007	In cultured rat cortical neurons, where constitutive expression was seen with all groups I, II and III mGluR subtypes, a significant and selective increase was seen in the DNA binding activity of AP1 120 min after the brief exposure to the group II mGluR agonist (2S,2"R,3"R)-2-(2",3"-dicarboxycyclopropyl)glycine (DCG-IV) for 5 min.	dcg	315-318	Jun proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	196-199
17559977-6	2007	Western blot analysis revealed differential expression profiles of Fos family members in neurons briefly exposed to DCG-IV and NMDA.	dcg	116-119	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	67-70
17174986-4	2007	In contrast, activation of groups II or III mGluRs by DCG-IV or l-AP4, respectively, failed to evoke any significant change in [Ca(2+)](i).	dcg	54-57	glutamate metabotropic receptor 1	Rattus norvegicus	44-50
17623021-6	2007	The suppression rate of MNTB-LSO IPSCs by DCG IV, an mGluR2/3 agonist, decreased with development and became negligible by the third week after birth.	dcg	42-45	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	53-59
16674916-3	2006	[(3)H]Quisqualic acid binding to mGluR1 required the presence of calcium (or magnesium) ions but not sodium or chloride ions while [(3)H]DCG-IV binding to mGluR3 was dependent upon both cations and anions.	dcg	137-140	glutamate receptor, ionotropic, AMPA3 (alpha 3)	Mus musculus	155-161
17179862-5	2006	Activation of metabotropic glutamate receptor 3 with (2"S,2"R,3"R)-2-(2",3"-dicarboxycyclopropyl)glycine-IV (DCG-IV) inhibited astrocyte proliferation without affecting metabotropic glutamate receptor 5-mediated phospholipase D activity.	dcg	109-112	glutamate metabotropic receptor 3	Homo sapiens	14-47
17179862-5	2006	Activation of metabotropic glutamate receptor 3 with (2"S,2"R,3"R)-2-(2",3"-dicarboxycyclopropyl)glycine-IV (DCG-IV) inhibited astrocyte proliferation without affecting metabotropic glutamate receptor 5-mediated phospholipase D activity.	dcg	109-112	glutamate metabotropic receptor 5	Homo sapiens	169-202
16868438-8	2006	In Cox regression models adjusted for age and established contributory markers in CCR5 and HLA class I genes, CTLA4-318T was associated with rapid progression to AIDS in MACS (relative hazard 1.69; 95% confidence interval, 1.15-2.49; P < 0.01) as opposed to a non-significant slower disease progression in ACS and no appreciable association in DCG.	dcg	347-350	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	110-115
16868438-8	2006	In Cox regression models adjusted for age and established contributory markers in CCR5 and HLA class I genes, CTLA4-318T was associated with rapid progression to AIDS in MACS (relative hazard 1.69; 95% confidence interval, 1.15-2.49; P < 0.01) as opposed to a non-significant slower disease progression in ACS and no appreciable association in DCG.	dcg	347-350	myristoylated alanine rich protein kinase C substrate	Homo sapiens	170-174
11978820-5	2002	These results suggest that small NMDA receptor-mediated responses evoked by single synaptic stimuli contribute to DCG IV-induced LTD. Third, DCG IV-induced LTD was blocked or reduced by the following drugs: phospholipase C inhibitor U-73122 (bath-applied or postsynaptically injected), postsynaptically injected IP3 receptor blocker heparin, phospholipase D-linked mGluR blocker PCCG-13, PKC inhibitor RO318220, postsynaptically injected PKC inhibitor PKC(19-36), and PKA inhibitor KT-5720.	dcg	141-144	inositol 1,4,5-trisphosphate receptor, type 3	Rattus norvegicus	312-324
16794859-4	2006	DCG-IV, an agonist of group II metabotropic glutamate receptors, caused a smaller decrease in S100B secretion when compared to 1 mM glutamate.	dcg	0-3	S100 calcium binding protein B	Homo sapiens	94-99
16707449-5	2006	Interestingly, cell surface labeling of cysteine cathepsins by the active site probe DCG-04 detected up-regulation of cathepsin X on PyMT;ctsb(-/-) cells.	dcg	85-88	cathepsin Z	Mus musculus	118-129
16707449-5	2006	Interestingly, cell surface labeling of cysteine cathepsins by the active site probe DCG-04 detected up-regulation of cathepsin X on PyMT;ctsb(-/-) cells.	dcg	85-88	cathepsin B	Mus musculus	138-142
16319172-2	2006	Previously, chromogranin A (CgA) has been shown to play a key role in the regulation of DCG biogenesis in vitro and in vivo.	dcg	88-91	chromogranin A	Homo sapiens	12-26
16319172-2	2006	Previously, chromogranin A (CgA) has been shown to play a key role in the regulation of DCG biogenesis in vitro and in vivo.	dcg	88-91	chromogranin A	Homo sapiens	28-31
16319172-3	2006	However, the underlying mechanism of CgA-mediated DCG biogenesis has not been explored.	dcg	50-53	chromogranin A	Homo sapiens	37-40
16319172-4	2006	In this study, we have uncovered a novel mechanism for the regulation of CgA-mediated DCG biogenesis.	dcg	86-89	chromogranin A	Homo sapiens	73-76
16319172-5	2006	Transfection of CgA into endocrine 6T3 cells lacking CgA and DCGs not only recovered DCG formation and regulated secretion but also prevented granule protein degradation.	dcg	61-64	chromogranin A	Homo sapiens	16-19
16319172-7	2006	Overexpression of PN-1 in CgA-deficient 6T3 cells prevented degradation of DCG proteins at the Golgi apparatus, enhanced DCG biogenesis, and recovered regulated secretion.	dcg	75-78	serpin family E member 2	Homo sapiens	18-22
16319172-7	2006	Overexpression of PN-1 in CgA-deficient 6T3 cells prevented degradation of DCG proteins at the Golgi apparatus, enhanced DCG biogenesis, and recovered regulated secretion.	dcg	75-78	chromogranin A	Homo sapiens	26-29
16049171-2	2005	Chromogranin A (CgA), which binds catecholamines for storage in the lumen of chromaffin granules, has been shown to be involved in DCG biogenesis in neuroendocrine PC12 cells.	dcg	131-134	chromogranin A	Rattus norvegicus	0-14
16049171-2	2005	Chromogranin A (CgA), which binds catecholamines for storage in the lumen of chromaffin granules, has been shown to be involved in DCG biogenesis in neuroendocrine PC12 cells.	dcg	131-134	chromogranin A	Rattus norvegicus	16-19
16049171-3	2005	Here, we report that downregulation of CgA expression in vivo by expressing antisense RNA against CgA in transgenic mice led to a significant reduction in DCG formation in adrenal chromaffin cells.	dcg	155-158	chromogranin A	Mus musculus	39-42
16049171-3	2005	Here, we report that downregulation of CgA expression in vivo by expressing antisense RNA against CgA in transgenic mice led to a significant reduction in DCG formation in adrenal chromaffin cells.	dcg	155-158	chromogranin A	Mus musculus	98-101
16049171-7	2005	These data indicate an essential role of CgA in regulating chromaffin DCG biogenesis and catecholamine storage in vivo.	dcg	70-73	chromogranin A	Mus musculus	41-44
15764838-4	2005	The injection of AVP4-9 ameliorated PA task performance impairment induced by DCG-IV, an mGluR2/3 agonist.	dcg	78-81	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	89-95
15993439-3	2005	Activation of group II mGluRs with the group-selective agonist DCG-IV or APDC reduced the amplitude of the evoked excitatory postsynaptic currents (EPSCs) and significantly increased the paired pulse ratio suggesting a presynaptic site of action.	dcg	63-66	glutamate receptor, metabotropic 2	Mus musculus	23-29
15993439-5	2005	Furthermore, we found that LY 487379, an mGluR2-specific allosteric modulator, significantly potentiated the inhibitory effect of DCG-IV on the excitatory transmission in the GP.	dcg	130-133	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	41-47
15652990-8	2005	Activation of mGluR3 with DCG-IV (but not of mGluR5 with DHPG) enhanced, in the presence of IL-1beta, the release of IL-6 in a dose dependent manner in astrocytes cultured under conditions (+EGF) in which the mGluR expression is known to be upregulated.	dcg	26-29	glutamate receptor, ionotropic, AMPA3 (alpha 3)	Mus musculus	14-20
15652990-8	2005	Activation of mGluR3 with DCG-IV (but not of mGluR5 with DHPG) enhanced, in the presence of IL-1beta, the release of IL-6 in a dose dependent manner in astrocytes cultured under conditions (+EGF) in which the mGluR expression is known to be upregulated.	dcg	26-29	interleukin 6	Homo sapiens	117-121
15178451-1	2004	In this study, 10 truncated constructs encompassing all or part of the extracellular ligand binding domain of the mGluR3 subtype of metabotropic glutamate receptor were generated, expressed in human embryonic kidney cells, and tested for secretion and binding of the high affinity agonist [(3)H]DCG-IV.	dcg	295-298	glutamate receptor, ionotropic, AMPA3 (alpha 3)	Mus musculus	114-120
15081789-5	2004	The DHPG, DCG-IV and L-AP4 effects on miniature IPSCs were dose dependent (EC(50)s=1.4, 0.055 and 0.52 microM, respectively) and were reduced by the selective mGluR antagonists MCPG, EGLU and MSOP, respectively.	dcg	10-13	replication initiator 1	Rattus norvegicus	23-26
12887692-2	2003	Ten of the 12 mGlu3 mutants (R64A, R68A, Y150A, S151A, T174A, D194A, Y222A, R277A, D301A and K389) showed either no binding or a 90% or greater loss of specific [3H]DCG-IV binding.	dcg	165-168	glutamate receptor, metabotropic 3	Mus musculus	14-19
12887692-4	2003	These results demonstrate that the binding of [3H]DCG-IV to mGlu3 is exceptionally sensitive to mutagenesis-induced perturbations.	dcg	50-53	glutamate receptor, metabotropic 3	Mus musculus	60-65
12887692-5	2003	In silico docking of DCG-IV into the agonist binding pocket of mGlu3 facilitated the interpretation the mutagenesis results.	dcg	21-24	glutamate receptor, metabotropic 3	Mus musculus	63-68
12653974-3	2003	Activation of type 1 cannabinoid receptors (CB1) by WIN 55,212-2 occluded the DCG IV-induced depression in a mutually occlusive manner.	dcg	78-81	cannabinoid receptor 1	Rattus norvegicus	44-47
12653974-10	2003	We suggest that CB1 receptor and group II mGlu signalling may interact through a presynaptic mechanism in the induction of a DCG IV-induced depression.	dcg	125-128	cannabinoid receptor 1	Rattus norvegicus	16-19
12614345-10	2003	In OPCs the group II mGluR agonist (2S,2"R,3"R)-2-(2",3"-dicarboxycyclopropyl)glycine (DCG-IV) decreased forskolin-stimulated cAMP synthesis, indicating the presence of functional mGluR3.	dcg	87-90	glutamate receptor, ionotropic, AMPA3 (alpha 3)	Mus musculus	180-186
15337307-6	2004	Furthermore, this stimulatory effect was totally abolished by the metabotropic glutamate ligands DHPG, DCG-IV and l-AP4, attenuated by the ionotropic non-NMDA glutamate receptor agonist AMPA and had no interference of the NMDA receptor antagonist MK-801.	dcg	103-106	glutamate ionotropic receptor NMDA type subunit 2C	Rattus norvegicus	154-177
12213275-3	2002	Field excitatory postsynaptic potentials evoked by stimulation of either the perforant path inputs to the dentate gyrus mid-moleculare or the CA1 stratum lacunosum moleculare were inhibited by DCG-IV with IC(50) values and maximum percentage inhibition of: 169 nM (60%) and 41 nM (72%) in wild-type mice and 273 nM (19%) and 116 nM (49%) in mGlu2 -/- mice, respectively.	dcg	193-196	carbonic anhydrase 1	Mus musculus	142-145
11208898-6	2001	Perfusion of DCG-IV induced an upregulation of striatal brain-derived neurotrophic factor (BDNF) mRNA expressing cells which were confined precisely around the microdialysis probe.	dcg	13-16	brain-derived neurotrophic factor	Rattus norvegicus	56-89
11805343-3	2002	Direct mGluR2 activation by (2S,2"R,3"R-2-(2",3"-dicarboxycyclopropyl)glycine (DCG-IV) persistently depressed layer 2/3 field potentials in slices of mouse binocular zone when stimulated concomitantly.	dcg	79-82	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	7-13
12373537-8	2002	In contrast, repeated DCG-IV (3 x 1 nmol/4 microl icv) injections enhanced both the control and the haloperidol-increased levels of PENK expression.	dcg	22-25	proenkephalin	Rattus norvegicus	132-136
12373538-9	2002	However, inhibitory effect of DCG-IV on dopamine release can be induced by attenuation of excitatory input from corticostriatal terminals by activation of mGluR2/3.	dcg	30-33	glutamate receptor, metabotropic 2	Mus musculus	155-163
12182892-0	2002	DCG-IV but not other group-II metabotropic receptor agonists induces microglial BDNF mRNA expression in the rat striatum.	dcg	0-3	brain-derived neurotrophic factor	Rattus norvegicus	80-84
11412903-1	2001	DCG-IV, a type 2 metabotropic glutamate receptor (mGluR2) agonist, was infused into the main olfactory bulb of 1-week-old pups exposed to peppermint odor.	dcg	0-3	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	50-56
11381723-1	2001	This paper investigates the impact of the Medicare principal inpatient diagnostic cost group (PIP-DCG) payment model on the Program of All-Inclusive Care for the Elderly (PACE).	dcg	98-101	furin, paired basic amino acid cleaving enzyme	Homo sapiens	171-175
11279263-9	2001	omega-Conotoxin GVIA and DCG-IV partially blocked kainic acid-induced enhancement of BDNF, indicating involvement of L-type and N-type voltage-dependent calcium channels, respectively.	dcg	25-28	brain-derived neurotrophic factor	Rattus norvegicus	85-89
11208898-7	2001	Taken together, our results suggest that the induction and release of brain-derived neurotrophic factor (BDNF) by activated glial cells induced by DCG-IV perfusion may account for its protective action against MPP+-induced dopaminergic terminal degeneration.	dcg	147-150	brain-derived neurotrophic factor	Rattus norvegicus	70-103
11208898-7	2001	Taken together, our results suggest that the induction and release of brain-derived neurotrophic factor (BDNF) by activated glial cells induced by DCG-IV perfusion may account for its protective action against MPP+-induced dopaminergic terminal degeneration.	dcg	147-150	brain-derived neurotrophic factor	Rattus norvegicus	105-109
11208898-6	2001	Perfusion of DCG-IV induced an upregulation of striatal brain-derived neurotrophic factor (BDNF) mRNA expressing cells which were confined precisely around the microdialysis probe.	dcg	13-16	brain-derived neurotrophic factor	Rattus norvegicus	91-95
10205782-4	1999	Among various compounds tested, (2S, 1"R, 2"R, 3"R)-2-(2,3-dicarboxycyclopropyl) glycine (DCG-IV) was found to be an effective agonist for mGluR2 and alpha-methyl-4-carboxyphenylglycine (alpha M4CPG) was found to be an antagonist for both mGluR1 and mGluR2.	dcg	90-93	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	139-145
10902895-0	2000	Differential effects of the group II mGluR agonist, DCG-IV, on depolarization-induced suppression of inhibition in hippocampal CA1 and CA3 neurons.	dcg	52-55	carbonic anhydrase 1	Rattus norvegicus	127-130
10902895-0	2000	Differential effects of the group II mGluR agonist, DCG-IV, on depolarization-induced suppression of inhibition in hippocampal CA1 and CA3 neurons.	dcg	52-55	carbonic anhydrase 3	Rattus norvegicus	135-138
10381595-7	1999	A quantitative analysis of the inhibition of presynaptic Ca2+ influx and field EPSP suggested that DCG-IV suppressed the field EPSP to a greater extent than would be expected if the suppression were solely due to a decrease in the presynaptic Ca2+ influx.	dcg	99-102	carbonic anhydrase 2	Mus musculus	57-60
10381595-7	1999	A quantitative analysis of the inhibition of presynaptic Ca2+ influx and field EPSP suggested that DCG-IV suppressed the field EPSP to a greater extent than would be expected if the suppression were solely due to a decrease in the presynaptic Ca2+ influx.	dcg	99-102	carbonic anhydrase 2	Mus musculus	243-246
10381595-9	1999	DCG-IV at 1 microM suppressed the mean frequency (to 73.8 +/- 3.9% of control, n = 11), but not the mean amplitude (to 97.0 +/- 3.5%), of miniature EPSCs recorded from CA3 neurones using the whole-cell patch-clamp technique.	dcg	0-3	carbonic anhydrase 3	Mus musculus	168-171
10205782-4	1999	Among various compounds tested, (2S, 1"R, 2"R, 3"R)-2-(2,3-dicarboxycyclopropyl) glycine (DCG-IV) was found to be an effective agonist for mGluR2 and alpha-methyl-4-carboxyphenylglycine (alpha M4CPG) was found to be an antagonist for both mGluR1 and mGluR2.	dcg	90-93	glutamate receptor, metabotropic 1	Mus musculus	239-245
10205782-4	1999	Among various compounds tested, (2S, 1"R, 2"R, 3"R)-2-(2,3-dicarboxycyclopropyl) glycine (DCG-IV) was found to be an effective agonist for mGluR2 and alpha-methyl-4-carboxyphenylglycine (alpha M4CPG) was found to be an antagonist for both mGluR1 and mGluR2.	dcg	90-93	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	250-256
10205782-5	1999	Using DCG-IV, I showed that mGluR2 mediates presynaptic inhibition of GABA release from granule cells at the dendrodendritic synapse of the accessory olfactory bulb (AOB).	dcg	6-9	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	28-34
10205782-7	1999	I also show that an activation of mGluR2 in AOB by infusion of DCG-IV induces olfactory memory, which can mimic the pregnancy block phenomenon of female mice.	dcg	63-66	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	34-40
8782108-4	1996	Application of a novel and potent mGluR2/mGluR3-specific agonist (2S,1"R,2"R,3"R)-2-(2,3-dicarboxycyclopropyl)glycine (DCG-IV, 0.1 microM) reversibly suppressed field excitatory postsynaptic potentials evoked by mossy fibre stimulation.	dcg	119-122	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	34-40
10193900-7	1999	Evidence for involvement of protein kinase C (PKC) and protein kinase (PKA) in the induction of LTD by activation of mGluRII was obtained by showing an inhibition of the DCG-IV-induced LTD by the PKC inhibitors Ro-31-8220 and bisindolylmaleimide I, and also by the PKA inhibitor H-89.	dcg	170-173	KIT proto-oncogene receptor tyrosine kinase	Rattus norvegicus	28-42
10193900-7	1999	Evidence for involvement of protein kinase C (PKC) and protein kinase (PKA) in the induction of LTD by activation of mGluRII was obtained by showing an inhibition of the DCG-IV-induced LTD by the PKC inhibitors Ro-31-8220 and bisindolylmaleimide I, and also by the PKA inhibitor H-89.	dcg	170-173	KIT proto-oncogene receptor tyrosine kinase	Rattus norvegicus	55-69
10193900-7	1999	Evidence for involvement of protein kinase C (PKC) and protein kinase (PKA) in the induction of LTD by activation of mGluRII was obtained by showing an inhibition of the DCG-IV-induced LTD by the PKC inhibitors Ro-31-8220 and bisindolylmaleimide I, and also by the PKA inhibitor H-89.	dcg	170-173	KIT proto-oncogene receptor tyrosine kinase	Rattus norvegicus	71-74
10193900-7	1999	Evidence for involvement of protein kinase C (PKC) and protein kinase (PKA) in the induction of LTD by activation of mGluRII was obtained by showing an inhibition of the DCG-IV-induced LTD by the PKC inhibitors Ro-31-8220 and bisindolylmaleimide I, and also by the PKA inhibitor H-89.	dcg	170-173	KIT proto-oncogene receptor tyrosine kinase	Rattus norvegicus	265-268
9098684-0	1997	DCG-IV inhibits synaptic transmission by activation of NMDA receptors in area CA1 of rat hippocampus.	dcg	0-3	carbonic anhydrase 1	Rattus norvegicus	78-81
8961193-9	1996	Both DSI and DCG-IV-induced inhibition are inhibited by L-2-amino-3-phosphonopropionic acid (L-AP3), a drug which interferes with several subtypes of mGluRs.	dcg	13-16	leucine aminopeptidase 3	Rattus norvegicus	93-98
8782108-4	1996	Application of a novel and potent mGluR2/mGluR3-specific agonist (2S,1"R,2"R,3"R)-2-(2,3-dicarboxycyclopropyl)glycine (DCG-IV, 0.1 microM) reversibly suppressed field excitatory postsynaptic potentials evoked by mossy fibre stimulation.	dcg	119-122	glutamate receptor, ionotropic, AMPA3 (alpha 3)	Mus musculus	41-47
7472317-8	1995	The compound (2S,1"R,2"R,3"R)-2-(2.3-dicarboxycyclopropyl)glycine (DCG-IV) activates both mGluR2 and mGluR3 at submicromolar concentrations, whereas it is inactive at mGluR4 and mGluR1, suggesting that this compound may be selective for group II mGluRs.	dcg	67-70	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	90-96
8556329-5	1995	Application of DCG-IV, a novel mGluR2/mGluR3-selective agonist, suppressed field EPSPs only slightly even at a high dose (3 microM).	dcg	15-18	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	31-37
8556329-5	1995	Application of DCG-IV, a novel mGluR2/mGluR3-selective agonist, suppressed field EPSPs only slightly even at a high dose (3 microM).	dcg	15-18	glutamate receptor, ionotropic, AMPA3 (alpha 3)	Mus musculus	38-44
7472317-8	1995	The compound (2S,1"R,2"R,3"R)-2-(2.3-dicarboxycyclopropyl)glycine (DCG-IV) activates both mGluR2 and mGluR3 at submicromolar concentrations, whereas it is inactive at mGluR4 and mGluR1, suggesting that this compound may be selective for group II mGluRs.	dcg	67-70	glutamate receptor, ionotropic, AMPA3 (alpha 3)	Mus musculus	101-107
7472317-8	1995	The compound (2S,1"R,2"R,3"R)-2-(2.3-dicarboxycyclopropyl)glycine (DCG-IV) activates both mGluR2 and mGluR3 at submicromolar concentrations, whereas it is inactive at mGluR4 and mGluR1, suggesting that this compound may be selective for group II mGluRs.	dcg	67-70	glutamate receptor, ionotropic, AMPA4 (alpha 4)	Mus musculus	167-173
7820650-2	1994	The enhancing effect of DCG-IV was (i) specific for mGluR agonists, (ii) restricted to hippocampal slice preparation, (iii) reversible, and (iv) not subject to homologous desensitization, in addition, DCG-IV did not interact with L-2-amino-4-phosphonobutanoate (AP4), a noncompetitive antagonist of mGluRs coupled to PPI hydrolysis in brain slices [32].	dcg	24-27	replication initiator 1	Rattus norvegicus	262-265
7727152-10	1995	DCG-IV significantly decreased in number of kainate-induced degenerated neurons in the area of hippocampal CA1, amygdala and septum when DCG-IV was continuously applied into the ventricule.	dcg	0-3	carbonic anhydrase 1	Homo sapiens	107-110
7836399-5	1995	The L chain of tetanus neurotoxin, known to inhibit granule mediated secretion in permeabilized PC12 cells, as well as botulinum neurotoxins F and G, effectively cleaved DCG-associated VAMP-2.	dcg	170-173	vesicle-associated membrane protein 2	Rattus norvegicus	185-191
7608756-6	1995	The metabotropic receptor antagonist R,S-alpha-methyl-4-carboxyphenylglycine (MCPG) blocked the synaptic depressant actions of DCG-IV and trans-1-aminocyclopentane-1,3-dicarboxylic acid (t-ACPD).	dcg	127-130	homer scaffold protein 2	Homo sapiens	189-193
7821331-9	1994	At relatively low doses, DCG-IV protected some kinds of neurons in the hippocampal CA3 and the amygdala against kainate neurotoxicity, when intraventricularly injected to the rat.	dcg	25-28	carbonic anhydrase 3	Rattus norvegicus	83-86
7517889-2	1994	As a neuroprotective agent, DCG-IV was much more potent than the mixed agonists 1S,3R-aminocyclopentane-1,3-dicarboxylic acid (1S,3R-ACPD) or (2S,1"S,2"S)-2-(carboxycyclopropyl)glycine (L-CCG-I), suggesting a neuroprotective role for mGluR2 or 3 against excitotoxic neuronal death.	dcg	28-31	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	234-240
33041371-5	2021	Among them, desacetylgedunin (DCG) found in Neem seed showed the highest binding affinity towards PLpro.	dcg	30-33	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	98-103
7903116-4	1993	Using the DCG-IV agonist for mGluR2 in combination with slice patch-recording, we demonstrate that the granule cell mGluR2 presynaptically suppresses inhibitory GABA (gamma-aminobutyrate) transmission to the mitral cell.	dcg	10-13	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	29-35
7903116-4	1993	Using the DCG-IV agonist for mGluR2 in combination with slice patch-recording, we demonstrate that the granule cell mGluR2 presynaptically suppresses inhibitory GABA (gamma-aminobutyrate) transmission to the mitral cell.	dcg	10-13	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	116-122
33041371-6	2021	Furthermore, MD-simulation studies supported by standard analysis (e.g. root mean square deviation and fluctuation (RMSD, RMSF), radius of gyration, solvent accessible surface area (SASA)) showed large impact on the structure of PLpro by DCG.	dcg	238-241	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	229-234
33041371-7	2021	We believe that the significant effect of DCG on PLpro may help in therapeutic efforts against SARS-CoV-2.	dcg	42-45	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	49-54
31183361-6	2019	Interestingly, our results showed that a mixed IL-9/IFNgamma secreting T cell response was induced when the tumour bearing mice received a low dose of DCG spore (1 x 108 CFU/kg), while a strong IFNgamma response was elicited with a high dosage of DCG spore (3 x 108 CFU/kg).	dcg	247-250	interleukin 9	Mus musculus	47-51
33266306-9	2020	The proform of cathepsin V was found to be reactive with the activity-based probe DCG-04, suggesting that it possesses catalytic activity.	dcg	82-85	cathepsin V	Homo sapiens	15-26
31183361-6	2019	Interestingly, our results showed that a mixed IL-9/IFNgamma secreting T cell response was induced when the tumour bearing mice received a low dose of DCG spore (1 x 108 CFU/kg), while a strong IFNgamma response was elicited with a high dosage of DCG spore (3 x 108 CFU/kg).	dcg	151-154	interleukin 9	Mus musculus	47-51
31183361-6	2019	Interestingly, our results showed that a mixed IL-9/IFNgamma secreting T cell response was induced when the tumour bearing mice received a low dose of DCG spore (1 x 108 CFU/kg), while a strong IFNgamma response was elicited with a high dosage of DCG spore (3 x 108 CFU/kg).	dcg	151-154	interferon gamma	Mus musculus	52-60
29213077-7	2017	These PAMs enhance the inhibitory action of the orthosteric mGlu2/mGlu3 agonist, DCG-IV, at mossy fiber terminals in the CA3 region of hippocampal slices.	dcg	81-84	glutamate receptor, metabotropic 3	Mus musculus	66-71
27354637-0	2016	Host CD40 Is Essential for DCG Treatment Against Metastatic Lung Cancer.	dcg	27-30	CD40 antigen	Mus musculus	5-9
27354637-6	2016	The functional activities of NK and NKT cells in DCG-treated CD40(-/-) mice were partially suppressed.	dcg	49-52	CD40 antigen	Mus musculus	61-65
27354637-7	2016	CONCLUSION: Host CD40 is essential for DCG treatment to have a therapeutic effect on B16F10 lung metastases.	dcg	39-42	CD40 antigen	Mus musculus	17-21
27354638-4	2016	RESULTS: While ALT levels were elevated after DCG in a tumor necrosis factor (TNF)-alpha-dependent manner, DCG did not cause lethal injury.	dcg	46-49	glutamic pyruvic transaminase, soluble	Mus musculus	15-18
27354638-4	2016	RESULTS: While ALT levels were elevated after DCG in a tumor necrosis factor (TNF)-alpha-dependent manner, DCG did not cause lethal injury.	dcg	46-49	tumor necrosis factor	Mus musculus	55-88
27354638-5	2016	More serious injury of liver CD31-positive endothelial cells (CD31(+) EC) was observed in mice treated with alphaGalCer than with DCG.	dcg	130-133	platelet/endothelial cell adhesion molecule 1	Mus musculus	29-33
27354638-5	2016	More serious injury of liver CD31-positive endothelial cells (CD31(+) EC) was observed in mice treated with alphaGalCer than with DCG.	dcg	130-133	platelet/endothelial cell adhesion molecule 1	Mus musculus	62-66
24206109-4	2014	These reductions were effectively restored by mGluR2/3 activation with mGluR2/3 agonists, LY379268 or DCG-IV, after the 6 h OGD insult.	dcg	102-105	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	46-52
29024451-5	2018	Stimulation of mGluR2/3 receptors during cell propagation using the agonist (2S,2"R,3"R)-2-(2",3"-dicarboxycyclopropyl) glycine (DCG-IV) increased total cell numbers significantly (60% compared to untreated controls).	dcg	129-132	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	15-21
26748052-5	2017	In cells expressing hmGlu2 receptors, LY3020371.HCl potently blocked mGlu2/3 agonist (DCG-IV)-inhibited, forskolin-stimulated cAMP formation (IC50 = 16.2 nM), an effect that was similarly observed in hmGlu3-expressing cells (IC50 = 6.21 nM).	dcg	86-89	glutamate receptor, metabotropic 3	Mus musculus	69-76
27383710-6	2016	The TNF-alpha expression showed a significant reduction from the 5th to the 10th day in NCG (p=0.0266) and DCG (p=0.0062).	dcg	107-110	tumor necrosis factor	Rattus norvegicus	4-13
22445601-6	2013	Co-application of DCG-IV and LY541850 in mGlu3-/- and wild-type littermates resulted in an additive effect, whereas in mGlu2-/- mice, LY541850 reversed the inhibitory action of DCG-IV.	dcg	18-21	glutamate receptor, metabotropic 3	Mus musculus	41-46
23167899-6	2013	Genetic ablation of mGluR2 markedly impaired the effects of DCG-IV and LY341495 on dendrodendritic inhibition.	dcg	60-63	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	20-26